Thera-SAbDab

CERTOLIZUMAB

>   Structural Summary
TherapeuticCertolizumab
TargetTNFA
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK
100% seqID Fv Structure5wuv [Fvs: HL], 5wux [Fvs: AB, CD, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFab
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2004
INN Year Recommended2004
Companies InvolvedUCB
Conditions ApprovedAnkylosing spondylitis, Crohn's disease, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Spondylitis, Non-radiographic axial spondyloarthritis
Conditions ActiveInterstitial cystitis, Juvenile rheumatoid arthritis
Conditions DiscontinuedCognition disorders
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]